Table 1 Main Characteristics of All Studies Included in the Meta-Analysis

Table 1 Main characteristics of all studies included in the meta-analysis

First author/year / Country / Ethnicity / Cancer type / CC / SC / HWE
CYP1B1 Leu432Val (rs1056836)
Martínez-Ramírezet al. 2013 / Mexico / Mixed / Breast cancer / 150–150 / HB / 0.164
Redinget al. 2012 / USA / Caucasian / Breast cancer / 1,138–981 / PB / 0.590
Redinget al. 2012 / USA / African / Breast cancer / 481–445 / PB / 0.952
Cerneet al. 2011 / Slovenia / Caucasian / Breast cancer / 523–269 / HB / 1.000
dos Santoset al. 2011 / Brazil / Mixed / Breast cancer / 62–62 / HB / NA
Ozbeket al. 2010 / Turkey / Caucasian / Breast cancer / 59–89 / HB / 0.620
Wanget al. 2011 / China / Asian / Breast cancer / 400–400 / PB / 0.044
Delortet al. 2010 / French / Caucasian / Breast cancer / 911–1,000 / PB / 0.515
Thyagarajan et al. 2004 / Brazil / Mixed / Breast cancer / 164-338 / PB / 0.077
Yadavet al. 2009 / India / Asian / Breast cancer / 154–166 / HB / 0.001
MARIE-GENICAet al. 2010 / Germany / Caucasian / Breast cancer / 3,146–5,487 / PB / 0.966
Sangrajranget al. 2009 / Thailand / Asian / Breast cancer / 553–490 / HB / 0.865
Katoet al. 2009 / USA / African / Breast cancer / 182–189 / PB / 0.183
Shimadaet al. 2009 / Brazil / Mixed / Breast cancer / 484–484 / HB / 0.824
Shimadaet al. 2009 / Japan / Asian / Breast cancer / 389–389 / HB / 0.032
Sigurdsonet al. 2009 / USA / Mixed / Breast cancer / 819–1,078 / PB / 0.697
Okobiaet al. 2009 / Nigeria / African / Breast cancer / 228–226 / HB / 0.274
Diergaardeet al. 2008 / USA / Caucasian / Breast cancer / 320–645 / PB / NA
VanEmburghet al. 2008 / USA / Caucasian / Breast cancer / 381–412 / HB / 0.504
VanEmburghet al. 2008 / USA / African / Breast cancer / 52–77 / HB / 0.892
Matyjasiket al. 2007 / Poland / Caucasian / Breast cancer / 2,017–876 / PB / 0.925
Sillanpääet al. 2007 / Finland / Caucasian / Breast cancer / 481–479 / HB / 0.609
Gaudetet al. 2006 / Poland / Caucasian / Breast cancer / 1,918–2,224 / PB / 0.090
Gallicchioet al. 2006 / USA / Caucasian / Breast cancer / 75–1,136 / PB / 0.790
Le Marchandet al. 2005 / USA / Mixed / Breast cancer / 1,339–1,370 / PB / <0.001
Wenet al. 2005 / China / Asian / Breast cancer / 1,110–1,195 / PB / 0.405
Zimarinaet al. 2004 / Russia / Caucasian / Breast cancer / 192–132 / HB / 0.386
Dunninget al. 2004 / UK / Caucasian / Breast cancer / 1,617–845 / PB / 0.606
Ahsanet al. 2004 / USA / Mixed / Breast cancer / 314–264 / FB / 0.980
Rylander-Rudqvistet al. 2003 / Sweden / Caucasian / Breast cancer / 1,489–1,334 / PB / 0.946
Leeet al. 2003 / Korea / Asian / Breast cancer / 241–290 / HB / 0.770
Kocabaşet al. 2002 / Turkey / Caucasian / Breast cancer / 84–103 / HB / 0.092
De Vivoet al. 2002 / USA / Caucasian / Breast cancer / 453–453 / PB / 0.135
Watanabeet al. 2000 / Japan / Asian / Breast cancer / 334–324 / PB / 0.763
Zheng et al. 2000 / China / Asian / Breast cancer / 186–200 / PB / 0.078
Baileyet al. 1998 / USA / Caucasian / Breast cancer / 164–164 / HB / 0.025
Baileyet al. 1998 / USA / African / Breast cancer / 59–59 / HB / 0.310
Listgartenet al. 2004 / Canada / Caucasian / Breast cancer / 173–154 / HB / 0.133
Li et al. 2002 / USA / Mixed / Breast cancer / 64–54 / HB / 0.365
Churchet al. 2010 / USA / Mixed / Lung cancer / 99–99 / PB / 0.422
Coteet al. 2009 / USA / Caucasian / Lung cancer / 254–323 / PB / 0.431
Coteet al. 2009 / USA / African / Lung cancer / 100–126 / PB / 0.908
Shahet al. 2008 / India / Asian / Lung cancer / 200–200 / HB / 1.000
Zienolddinyet al. 2008 / Norway / Caucasian / Lung cancer / 240–297 / PB / 0.202
Yoonet al. 2008 / Korea / Asian / Lung cancer / 214–213 / HB / 0.518
Wenzlaffet al. 2005 / USA / Caucasian / Lung cancer / 129–148 / PB / 0.128
Wenzlaffet al. 2005 / USA / African / Lung cancer / 28–30 / PB / 1.000
Lianget al. 2005 / China / Asian / Lung cancer / 227–227 / HB / 0.401
Sørensenet al. 2005 / Denmark / Caucasian / Lung cancer / 256–269 / PB / 0.706
Wuet al. 2004 / China / Asian / Lung cancer / 42–58 / HB / NA
Watanabeet al. 2000 / Japan / Asian / Lung cancer / 330–324 / PB / 0.763
Timofeevaet al. 2009 / German / Caucasian / Lung cancer / 615–1,262 / PB / 0.777
Wanget al. 2012 / USA / Mixed / Colorectal cancer / 300–350 / FB / 0.059
Rudolphet al. 2011 / German / Caucasian / Colorectal cancer / 668–669 / PB / 0.515
Sainzet al. 2011 / German / Caucasian / Colorectal cancer / 719–713 / PB / 0.547
Clearyet al. 2010 / Canada / Caucasian / Colorectal cancer / 1162–1291 / PB / 0.649
Hlavataet al. 2010 / Czech / Caucasian / Colorectal cancer / 495–495 / HB / 0.172
Trubickaet al. 2010 / Poland / Caucasian / Colorectal cancer / 597–598 / PB / 0.061
Cotterchioet al. 2008 / Canada / Caucasian / Colorectal cancer / 831–1248 / PB / 0.894
Küryet al.2007 / France / Caucasian / Colorectal cancer / 1,013–1,118 / PB / 0.112
Bethkeet al. 2007 / UK / Caucasian / Colorectal cancer / 2,559–2,695 / HB / 0.518
Huberet al. 2005 / Australia / Caucasian / Colorectal cancer / 42–337 / HB / NA
Landiet al. 2005 / Spain / Caucasian / Colorectal cancer / 343–299 / HB / 0.669
Sachseet al. 2002 / UK / Caucasian / Colorectal cancer / 490–593 / PB / 0.708
Lundinet al. 2012 / Sweden / Caucasian / Endometrial cancer / 391–704 / HB / 0.903
Zhuet al. 2011 / China / Asian / Endometrial cancer / 72–80 / HB / 0.093
Sliwinskiet al.2010 / Poland / Caucasian / Endometrial cancer / 100–100 / HB / 0.001
Ashtonet al. 2010 / Australia / Caucasian / Endometrial cancer / 191–290 / PB / 0.981
Hirataet al. 2008 / USA / Caucasian / Endometrial cancer / 150–165 / HB / 0.319
Taoet al. 2006 / China / Asian / Endometrial cancer / 1,037–1,034 / PB / 0.130
Dohertyet al. 2005 / USA / Mixed / Endometrial cancer / 371–420 / PB / 0.529
Rylander-Rudqvistet al. 2004 / Sweden / Caucasian / Endometrial cancer / 665–1,380 / PB / 0.976
Zimarinaet al. 2004 / Russia / Caucasian / Endometrial cancer / 121–132 / HB / 0.386
McGrathet al. 2004 / USA / Caucasian / Endometrial cancer / 219–655 / PB / 0.739
Sasakiet al. 2003 / Japan / Asian / Endometrial cancer / 113–202 / HB / 0.087
Rebbecket al. 2006 / USA / Mixed / Endometrial cancer / 502–1,326 / HB / NA
Catsburget al. 2012 / USA / Mixed / Prostate cancer / 1,419–756 / PB / 0.009
Beutenet al. 2008 / USA / Caucasian / Prostate cancer / 633–733 / PB / 0.091
Cussenotet al. 2007 / France / Caucasian / Prostate cancer / 1,053–837 / HB / 0.987
Berndtet al. 2007 / USA / Mixed / Prostate cancer / 486–611 / PB / 0.801
Sobtiet al. 2006 / India / Asian / Prostate cancer / 100–100 / HB / 0.513
Ciceket al. 2005 / USA / Mixed / Prostate cancer / 439–479 / HB / 0.008
Fukatsuet al. 2004 / Korea / Asian / Prostate cancer / 241–290 / HB / 0.770
Changet al. 2003 / USA / Caucasian / Prostate cancer / 310–182 / HB / NA
Tanakaet al. 2002 / Japan / Asian / Prostate cancer / 119–200 / HB / 0.008
Tanget al. 2000 / USA / Caucasian / Prostate cancer / 50–50 / HB / NA
Holtet al. 2013 / USA / Caucasian / Prostate cancer / 1256–1235 / PB / 0.766
Delortet al. 2008 / France / Caucasian / Ovarian cancer / 51–1000 / PB / 0.515
Holtet al. 2007 / USA / Caucasian / Ovarian cancer / 277–447 / PB / 0.912
Holtet al. 2007 / USA / African / Ovarian cancer / 33–127 / PB / 0.564
Sellerset al. 2005 / USA / Caucasian / Ovarian cancer / 454–545 / HB / 1.000
Sellerset al. 2005 / USA / African / Ovarian cancer / 36–53 / HB / <0.001
Goodman et al. 2001 / USA / Mixed / Ovarian cancer / 128–144 / PB / 0.709
Cecchinet al. 2004 / Italy / Caucasian / Ovarian cancer / 220–280 / HB / 0.999
Souceket al. 2010 / Poland / Caucasian / HNC / 116–122 / HB / 0.073
Taiet al. 2010 / China / Asian / HNC / 271–271 / HB / 0.296
Harthet al. 2008 / German / Caucasian / HNC / 312–300 / HB / 0.727
Singhet al. 2008 / India / Asian / HNC / 150–150 / HB / 0.883
Liet al. 2005 / USA / Caucasian / HNC / 724–1226 / HB / 0.979
Koet al. 2001 / German / Caucasian / HNC / 312–300 / HB / 0.727
Mauryaet al. 2014 / India / Asian / HNC / 750–749 / HB / 0.033
Berberet al. 2013 / Turkey / Caucasian / Bladder cancer / 114–114 / HB / 0.186
Salinas-Sánchezet al. 2012 / Spain / Caucasian / Bladder cancer / 208–208 / HB / 0.279
Fontanaet al. 2009 / France / Caucasian / Bladder cancer / 51–45 / HB / 1.000
Figueroaet al. 2008 / Spain / Caucasian / Bladder cancer / 1084–1011 / HB / 0.450
Hung et al. 2004 / Italy / Caucasian / Bladder cancer / 201–214 / HB / 0.816
Janget al. 2012 / Canada / Mixed / Pancreatic cancer / 449–887 / PB / 0.622
Salinas-Sánchezet al. 2011 / Spain / Caucasian / Renal cell cancer / 126–208 / HB / 0.279
Kilfoyet al. 2009 / USA / Caucasian / NHL / 444–520 / PB / NA
Yuanet al. 2008 / China / Asian / Hepatocellular cancer / 429–480 / HB / 0.892
Freedmanet al. 2009 / Poland / Caucasian / Gastric cancer / 292–413 / PB / 0.976
De Rooset al. 2006 / USA / Mixed / Lymphoma / 1107–920 / PB / 0.093
DeRooset al. 2006 / USA / Mixed / Glioma / 368–518 / HB / 0.558
Sasakiet al. 2004 / Japan / Asian / Renal cell cancer / 211–200 / HB / 0.008
Vranaet al. 2010 / Czech / Caucasian / Pancreatic cancer / 247–468 / HB / 0.032
Liet al. 2013 / China / Asian / Cervical cancer / 250–250 / HB / 0.266
CYP1B1 Asn453Ser (rs1800440)
MARIE-GENICAet al. 2010 / German / Caucasian / Breast cancer / 3146–5486 / PB / 0.545
Redinget al. 2012 / USA / Caucasian / Breast cancer / 1136–983 / PB / 0.970
Redinget al. 2012 / USA / African / Breast cancer / 482–447 / PB / 1.000
Gaudetet al. 2006 / Poland / Caucasian / Breast cancer / 1,897–2,175 / PB / 0.492
Delortet al. 2010 / French / Caucasian / Breast cancer / 911–1,000 / PB / 0.816
Ahsanet al. 2004 / USA / Mixed / Breast cancer / 315–264 / FB / 0.602
Gallicchioet al. 2006 / USA / Caucasian / Breast cancer / 86–1,261 / PB / 1.000
Li et al. 2002 / USA / Mixed / Breast cancer / 64–54 / HB / 0.344
Huanget al.2009 / USA / Caucasian / Breast cancer / 1,618–1,417 / PB / 0.924
De Vivoet al. 2002 / USA / Caucasian / Breast cancer / 453–453 / PB / 0.963
Baileyet al. 1998 / USA / Caucasian / Breast cancer / 164–164 / HB / 0.873
Baileyet al. 1998 / USA / African / Breast cancer / 59–59 / HB / 0.970
Rylander-Rudqvistet al. 2003 / Sweden / Caucasian / Breast cancer / 1,484–1,336 / PB / 0.482
Matyjasiket al. 2007 / Poland / Caucasian / Breast cancer / 2,017–744 / PB / 0.993
Diergaardeet al. 2008 / USA / Caucasian / Breast cancer / 319–643 / PB / NA
Zienolddinyet al. 2008 / Norway / Caucasian / Lung cancer / 233–291 / PB / 0.163
Shahet al. 2008 / India / Asian / Lung cancer / 200–200 / HB / 0.988
Churchet al. 2010 / USA / Mixed / Lung cancer / 94–96 / PB / 0.544
Rotunnoet al. 2009 / USA / Caucaisan / Lung cancer / 1,865–2,032 / PB / 0.999
Timofeevaet al. 2009 / German / Caucasian / Lung cancer / 617–1,268 / PB / 0.819
Landiet al. 2005 / Spain / Caucasian / Colorectal cancer / 342–297 / HB / 0.357
Sainzet al. 2011 / German / Caucasian / Colorectal cancer / 731–722 / PB / 0.989
Clearyet al. 2010 / Canada / Caucasian / Colorectal cancer / 1,163–1,292 / PB / 0.512
Huberet al. 2005 / Australia / Caucasian / Colorectal cancer / 42–332 / HB / NA
Rudolphet al. 2011 / German / Caucasian / Colorectal cancer / 676–680 / PB / 0.846
Hlavataet al. 2010 / Czech / Caucasian / Colorectal cancer / 495–495 / HB / 0.248
Bethkeet al. 2007 / UK / Caucasian / Colorectal cancer / 2,559–2,694 / HB / 0.237
Cotterchioet al. 2008 / Canada / Caucasian / Colorectal cancer / 832–1,249 / PB / 0.484
Tanakaet al. 2002 / Japan / Asian / Prostate cancer / 117–200 / HB / 1.000
Beutenet al. 2008 / USA / Caucasian / Prostate cancer / 609–709 / PB / 0.869
Changet al. 2003 / USA / Caucasian / Prostate cancer / 314–182 / HB / NA
Berndtet al. 2007 / USA / Mixed / Prostate cancer / 484–608 / PB / 1.000
Delortet al. 2008 / France / Caucasian / Ovarian cancer / 51–1,000 / PB / 0.816
Holtet al. 2007 / USA / Caucasian / Ovarian cancer / 277–450 / PB / 1.000
Holtet al. 2007 / USA / African / Ovarian cancer / 33–127 / PB / 0.248
Lundinet al. 2012 / Sweden / Caucasian / Endometrial cancer / 389–709 / HB / NA
McGrathet al. 2004 / USA / Caucasian / Endometrial cancer / 218–658 / PB / 0.897
Rylander-Rudqvistet al. 2004 / Sweden / Caucasian / Endometrial cancer / 668–1378 / PB / 0.773
Ashtonet al. 2010 / Australia / Caucasian / Endometrial cancer / 191–288 / PB / 0.947
Rebbecket al. 2006 / USA / Mixed / Endometrial cancer / 502–1326 / HB / NA
Figueroaet al. 2008 / Spain / Caucasian / Bladder cancer / 1100–1022 / HB / 0.001
Salinas-Sánchezet al. 2012 / Spain / Caucasian / Bladder cancer / 208–208 / HB / 0.616
Singhet al. 2008 / India / Asian / HNC / 150–150 / HB / 0.767
Salinas-Sánchezet al. 2011 / Spain / Caucasian / Renal cell cancer / 126–208 / HB / 0.616
Janget al. 2012 / Canada / Mixed / Pancreatic cancer / 451–883 / PB / 0.142
Souceket al. 2010 / Poland / Caucasian / HNC / 116–122 / HB / 0.799
Vranaet al. 2010 / Czech / Caucasian / Pancreatic cancer / 247–469 / HB / 0.544
Freedman et al. 2009 / Poland / Caucasian / Gastric cancer / 295–414 / PB / 0.999
CYP1B1 Arg48Gly (rs10012)
Diergaardeet al. 2008 / USA / Caucasian / Breast cancer / 315–638 / PB / NA
Zimarinaet al. 2004 / Russia / Caucasian / Breast cancer / 185–144 / HB / 0.331
Gaudetet al. 2006 / Poland / Caucasian / Breast cancer / 1,963–2,258 / PB / 0.002
Matyjasiket al. 2007 / Poland / Caucasian / Breast cancer / 2,017–876 / PB / 0.547
MARIE-GENICAet al. 2010 / Germany / Caucasian / Breast cancer / 3,140–5,478 / PB / 0.174
Redinget al. 2012 / USA / Caucasian / Breast cancer / 1,138–984 / PB / 0.977
Redinget al. 2012 / USA / African / Breast cancer / 480–446 / PB / 0.004
Wenet al. 2005 / China / Asian / Breast cancer / 1,123–1,198 / PB / 0.981
Shimadaet al. 2009 / Brazil / Mixed / Breast cancer / 484–484 / HB / 0.265
Shimadaet al. 2009 / Japan / Asian / Breast cancer / 388–389 / HB / 0.981
Dunninget al. 2004 / UK / Caucasian / Breast cancer / 1,631–778 / PB / 0.799
Gallicchioet al. 2006 / USA / Caucasian / Breast cancer / 75–1,136 / PB / 0.626
Landiet al. 2005 / Spain / Caucasian / Colorectal cancer / 299–258 / HB / 0.917
Sainzet al. 2011 / German / Caucasian / Colorectal cancer / 729–718 / PB / 0.304
Clearyet al. 2010 / Canada / Caucasian / Colorectal cancer / 1,163–1,292 / PB / 0.960
Cotterchioet al. 2008 / Canada / Caucasian / Colorectal cancer / 832–1249 / PB / 1.000
Trubickaet al. 2010 / Poland / Caucasian / Colorectal cancer / 597–597 / PB / 0.998
Rudolphet al. 2011 / German / Caucasian / Colorectal cancer / 679–675 / PB / 0.407
Ashtonet al. 2010 / Australia / Caucasian / Endometrial cancer / 191–276 / PB / 1.000
Zimarinaet al. 2004 / Russia / Caucasian / Endometrial cancer / 127–144 / HB / 0.334
Sasakiet al. 2003 / Japan / Asian / Endometrial cancer / 113–202 / HB / 0.044
Taoet al. 2006 / China / Asian / Endometrial cancer / 1,038–1,031 / PB / 0.535
Sliwinskiet al. 2010 / Poland / Caucasian / Endometrial cancer / 100–100 / HB / 0.926
Holtet al. 2007 / USA / Caucasian / Ovarian cancer / 277–449 / PB / 0.997
Holtet al. 2007 / USA / African / Ovarian cancer / 33–126 / PB / 0.012
Sellerset al. 2005 / USA / Caucasian / Ovarian cancer / 453–543 / HB / 0.484
Sellerset al. 2005 / USA / African / Ovarian cancer / 36–53 / HB / 0.025
Berndtet al. 2007 / USA / Mixed / Prostate cancer / 469–593 / PB / 0.122
Beutenet al. 2009 / USA / African / Prostate cancer / 67–133 / PB / 0.299
Tanakaet al. 2002 / Japan / Asian / Prostate cancer / 117–200 / HB / 0.039
Beutenet al. 2008 / USA / Caucasian / Prostate cancer / 649–736 / PB / 0.248
Changet al. 2003 / USA / Caucasian / Prostate cancer / 345–184 / HB / NA
Figueroaet al. 2008 / Spain / Caucasian / Bladder cancer / 1,031–960 / HB / 0.031
Salinas-Sánchezet al. 2011 / Spain / Caucasian / Renal cell cancer / 123–208 / HB / 0.005
Janget al. 2012 / Canada / Mixed / Pancreatic cancer / 451–879 / PB / 0.858
Zienolddinyet al. 2008 / Norway / Caucasian / Lung cancer / 327–368 / PB / 0.767
Churchet al. 2010 / USA / Mixed / Lung cancer / 95–98 / PB / 0.053
Sasakiet al. 2004 / Japan / Asian / Renal cell cancer / 211–200 / HB / 0.039
CYP1B1 Ala119Ser (rs1056827)
Zimarinaet al. 2004 / Russia / Caucasian / Breast cancer / 169–142 / HB / 0.899
Watanabeet al. 2000 / Japan / Asian / Breast cancer / 339–361 / PB / 0.879
Matyjasiket al. 2007 / Poland / Caucasian / Breast cancer / 2,017–876 / PB / 0.998
VanEmburghet al. 2008 / USA / Caucasian / Breast cancer / 379–406 / HB / 0.818
VanEmburghet al. 2008 / USA / African / Breast cancer / 55–77 / HB / 0.843
Dunninget al. 2004 / UK / Caucasian / Breast cancer / 997–812 / PB / 0.699
MARIE-GENICAet al. 2010 / Germany / Caucasian / Breast cancer / 3,142–5,477 / PB / 0.497
Redinget al. 2012 / USA / Caucasian / Breast cancer / 1,138–985 / PB / 0.899
Redinget al. 2012 / USA / African / Breast cancer / 479–444 / PB / 0.010
Wenet al. 2005 / China / Asian / Breast cancer / 1,124–1,212 / PB / 0.763
Gulyaevaet al. 2008 / Russia / Caucasian / Breast cancer / 117-120 / HB / 0.008
Sainzet al. 2011 / German / Caucasian / Colorectal cancer / 729–718 / PB / 0.340
Rudolphet al. 2011 / German / Caucasian / Colorectal cancer / 675–678 / PB / 0.413
Trubickaet al. 2010 / Poland / Caucasian / Colorectal cancer / 597–597 / PB / 0.999
Holtet al. 2007 / USA / Caucasian / Ovarian cancer / 277–450 / PB / 1.000
Holtet al. 2007 / USA / African / Ovarian cancer / 33–126 / PB / 0.128
Sellerset al. 2005 / USA / Caucasian / Ovarian cancer / 453–543 / HB / 0.415
Sellerset al. 2005 / USA / African / Ovarian cancer / 36–53 / HB / 0.072
Zienolddinyet al. 2008 / Norway / Caucasian / Lung cancer / 280–330 / PB / 0.001
Watanabeet al. 2000 / Japan / Asian / Lung cancer / 326–361 / PB / 0.879
Churchet al. 2010 / USA / Mixed / Lung cancer / 95–98 / PB / 0.145
Timofeevaet al. 2009 / German / Caucasian / Lung cancer / 600–1,255 / PB / 0.386
Tanakaet al. 2002 / Japan / Asian / Prostate cancer / 117–200 / HB / 0.003
Changet al. 2003 / USA / Caucasian / Prostate cancer / 349–185 / HB / NA
Ciceket al. 2005 / USA / Mixed / Prostate cancer / 437–479 / HB / 0.884
Rodrigueset al. 2011 / Brazil / Mixed / Prostate cancer / 154–154 / HB / <0.001
Salinas-Sánchezet al. 2012 / Spain / Caucasian / Bladder cancer / 208–208 / HB / 0.011
Berberet al. 2013 / Turkey / Caucasian / Bladder cancer / 114–114 / HB / 0.894
Salinas-Sánchezet al. 2011 / Spain / Caucasian / Renal cell cancer / 122–208 / HB / 0.011
Zimarinaet al. 2004 / Russia / Caucasian / Endometrial cancer / 127–142 / HB / 0.899
Sasakiet al. 2003 / Japan / Asian / Endometrial cancer / 113–202 / HB / 0.026
Taoet al. 2006 / China / Asian / Endometrial cancer / 1,037–1,030 / PB / 0.122
Sasakiet al. 2004 / Japan / Asian / Renal cancer / 211–200 / HB / 0.003
Mauryaet al. 2014 / India / Asian / HNC / 750–750 / HB / <0.001

HNC Head and neck cancer, TGCT Testicular germ cell tumor, NHLnon-Hodgkin lymphoma, HB hospital-based studies, PB population-based studies, Y yes, N no, CC case–control